Sun Pharma Q3: PAT, EBITDA Margin Rise; Ranks #1 in Indian Pharma Market

  • Investing.com
  • Stock Market News
Sun Pharma Q3: PAT, EBITDA Margin Rise; Ranks #1 in Indian Pharma Market
Credit: © Reuters.

By Malvika Gurung

Investing.com -- The pharmaceutical behemoth Sun Pharmaceutical Industries (NS: SUN ) released its earnings result for the December ended quarter on Tuesday, with bottomline growth in line with the Street’s estimates.

The drugmaker recorded a 5.2% rise in net profit for the December quarter at Rs 2,166 crore from Rs 2,058.8 crore year-on-year, at par with Bloomberg’s estimate of Rs 2,086.12 crore.

Its revenue climbed 14% YoY to Rs 11,241 crore, and EBITDA advanced 15.2% YoY to Rs 3,003.7 crore. The pharma giant’s EBITDA margin expanded to 26.7% in Q3 FY23 from 26.5% in the corresponding quarter of last year.

Sun Pharma’s India formulation sales grew by 7.1% YoY to Rs 3,391.9 crore in Q3 FY23, accounting for about 31% of total consolidated sales, while the US formulation sales grew 6.3% YoY to $422 million in the period.

Further, the Mumbai–based pharma heavyweight ranks No. 1 in the Indian pharmaceutical market according to AIOCD AWACS MAT December 2022 report, and holds a market share of 8.5% in the industry worth over Rs 1,800 billion in Q3 FY23.

In the December 2021 quarter (Q3 FY22), Sun Pharma’s market share stood at 8.2%.

“Specialty is expected to continue as a key growth driver for Sun. We are investing to scale up this business, especially in our core therapy areas. Proposed Concert acquisition is a step forward in this direction,” said the company’s MD Dilip Shanghvi.

Sun Pharma also declared an interim dividend of Rs 7.5/share for FY23. To know more about it, continue reading Pharma Giant Announces Rs 7.5/Share Interim Dividend: Record, Payment Dates

Add Chart to Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100
Please try another search

Related Articles